Prescription Opioid and Heroin Epidemic Awareness Week closed Friday, but intense talks around the topic and related drug development haven't stopped and probably won't anytime soon.more »
When it comes to how drugs are priced in the U.S., everyone seems to agree on one thing: The system is broken. But before they can fix it, Congress and policymakers need to first understand how it is structured now and where the problems are.
Democrats and Republicans alike expressed disgust at a House oversight hearing Wednesday over Mylan NV’s “disgraceful” Epipen pricing and the unfathomable U.S. system that lets drug and device companies jack up their prices with no justification.
- U.S. drug pricing system is broken: Where do we go from here?
- Evaluating the value proposition: NICE chief sets conciliatory tone
- Iomx raises $45M for tumor-derived immune checkpoint targets
- One target for multiple lysosomal storage diseases
- Four-closure: Seelos deal with Ligand brings motley crew, hinges on financing
- CFDA continues reforms, cracks down on doubtful drug approval applications
- Toolgen wins critical CRISPR patent in Korea
- Innovent Biologics preps phase III trials for Mabthera, Humira biosimilars in China
- Sanofi, Vinapharm deal to open Vietnam market
- Australia gears up to reform drug, device regulations, speed access to therapies
The uptick in Parkinson's disease (PD) programs that began in the first half of this decade is accelerating across the span of drug development, leading to a recent approval, multiple candidates in late-stage development and M&A in the space. Although disease-modifying therapies – the Holy Grail of PD treatment – may be years or perhaps decades away, more effective forms of levodopa (L-dopa) treatment now are augmented by drugs designed to manage nonmotor symptoms.
A team from the University of Tuebingen has identified the first bactericidal compound produced by a member of the human microbiome.
- Reprogrammed stem cells transplanted without rejection »
- One target for multiple lysosomal storage diseases »
- Shutting down bile acid transport prevents fatty liver »
- Lipid synthesis inhibitor starves cancer cells »
- Single mouse strain research strains credibility, study shows »
- Promising new antibiotic, derivatives, synthesized »
- Targeting the smallest organ has large effects on blood pressure »
- Gene diversity can alter metabolic individuality »
- Chronic fatigue syndrome framed as hypometabolic disorder »
- Left on the garbage heap of the 114th Congress?September 02, 2016 | 4:57 PM | Posted by: Mari Serebrov
- Will biosimilar carve-outs put R&D for older MAbs on ice?August 11, 2016 | 10:47 PM | Posted by: Mari Serebrov
- Ethically speaking: What’s the right thing to do?July 29, 2016 | 7:41 PM | Posted by: Lynn Yoffee
- For the birds, or the BlackBerries: Titles to intrigue and entertain in BioWorld’s 10th Annual Summer Reading ListJune 01, 2016 | 7:52 PM | Posted by: Marie Powers
- An end to Charlotte’s web?May 10, 2016 | 9:09 PM | Posted by: Mari Serebrov
Partners in Focus
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter